Genetic markers of stable molecular remission in chronic myeloid leukemia after targeted therapy discontinuation

Leuk Lymphoma. 2018 Oct;59(10):2512-2515. doi: 10.1080/10428194.2018.1434880. Epub 2018 Feb 9.

Affiliations

¹ a Laboratory of Mutagenesis , FSBI "Research Centre for Medical Genetics" , Moscow , Russian Federation.
² b Scientific and Advisory Department of Chemotherapy of Myeloproliferative disorders , FSFI "National Research Center for Hematology" of the Ministry of Healthcare of the Russian Federation , Moscow , Russian Federation.
³ c Department of Molecular and Cellular Genetics , The Russian National Research Medical University Named after N.I. Pirogov , Moscow , Russian Federation.

PMID: 29424604
DOI: 10.1080/10428194.2018.1434880

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Validation Study

MeSH terms

Adult
Aged
Aged, 80 and over
Antineoplastic Agents / therapeutic use*
Biomarkers, Tumor / genetics*
Cytochrome P-450 CYP1B1 / genetics
Female
Follow-Up Studies
Fusion Proteins, bcr-abl / blood
Humans
Interferon Regulatory Factor-1 / genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / blood
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
Male
Middle Aged
Neoplasm Proteins / genetics
Neoplasm Recurrence, Local / diagnosis*
Neoplasm Recurrence, Local / genetics
Poly(ADP-ribose) Polymerases / genetics
Polymorphism, Single Nucleotide
Protein Kinase Inhibitors / therapeutic use*
Protein Kinases / genetics
Remission Induction / methods
Withholding Treatment

Substances

Antineoplastic Agents
Biomarkers, Tumor
IRF1 protein, human
Interferon Regulatory Factor-1
Neoplasm Proteins
PARP9 protein, human
Protein Kinase Inhibitors
CYP1B1 protein, human
Cytochrome P-450 CYP1B1
Poly(ADP-ribose) Polymerases
ALPK2 protein, human
Protein Kinases
Fusion Proteins, bcr-abl